Melasma: Why It Keeps Coming Back, and the Treatment Sequence That Actually Controls It

"It's back again, and I did everything right this time."

"I spent four hundred dollars on a brightening serum and it made absolutely no difference."

"My dermatologist gave me a cream years ago, it worked, and then it just stopped."

"I got a laser treatment somewhere else and my skin is darker now than before I started."

I hear some version of these sentences nearly every week in my practice, and I want to say clearly, before we go any further, that none of these patients did anything wrong. Melasma is, in my clinical opinion, one of the most misunderstood and most mismanaged conditions in all of dermatology, not because the science is unclear, but because the consumer-facing advice around it is almost uniformly incomplete. Patients are told to "brighten" their skin, to "exfoliate the dark spots away," to try a laser, to try a peel, to try a new serum every few months when the last one stopped working. Almost none of that advice addresses what melasma actually is, which is the single biggest reason it keeps coming back.

I want to spend this entire conversation walking through the real biology of melasma: what causes it, why it is so different from an ordinary sunspot or a leftover mark from a blemish, why so many well-intentioned treatments make it temporarily worse, and what an actual evidence-based, sequenced treatment plan looks like when it is built around the mechanism rather than around whatever ingredient happens to be trending that month. This is not a quick-fix conversation. Melasma does not have a quick fix, and I think patients deserve to hear that honestly, up front, from someone who treats it regularly, rather than discovering it after their third disappointing product purchase.

This is also not a seasonal conversation. I am not writing this because melasma is "having a moment" right now. It isn't, and it doesn't need to be, because it is one of the most persistently common pigmentary concerns I see walk through my doors in Alpharetta, across every season, every year, regardless of what is trending on social media. Understanding it properly is something that will serve you exactly as well five years from now as it does today.

What Melasma Actually Is, and Why It Is Not "Just a Dark Spot"

Let's start with the distinction that I think causes the most confusion, because nearly every patient who comes to see me about melasma initially describes it the same way other patients describe sunspots, age spots, or marks left behind from a healed pimple. They are not the same condition, and the difference matters enormously for treatment.

A sunspot, technically called a solar lentigo, results from localized overproduction of pigment by melanocytes that have been damaged by cumulative ultraviolet exposure over years. It is, in a sense, a fairly straightforward problem: a cluster of pigment-producing cells in one spot got overstimulated, and that spot is now darker than the surrounding skin. Post-inflammatory hyperpigmentation, the dark mark that lingers after a pimple, a cut, a burn, or an inflammatory skin reaction heals, is your skin's own healing response: inflammation triggers nearby melanocytes to dump extra pigment into the area as part of the repair process. Both of these are, generally speaking, contained, localized, and responsive to fairly standard pigment-targeting treatment once the underlying trigger resolves.

Melasma is a fundamentally different process, and understanding why is the single most important thing I can teach a patient about this condition.

In melasma, the melanocytes themselves, the pigment-producing cells distributed throughout the affected areas of skin, become chronically hyperresponsive. They are not damaged in the way a sunspot's melanocytes are damaged. They are, in a sense, recalibrated to a more reactive baseline, producing more pigment, more readily, in response to triggers that would barely register in unaffected skin. This is why melasma typically appears as broader, more symmetrical patches, frequently across the cheeks, the forehead, the upper lip, and the chin, rather than as the isolated, well-defined spots characteristic of sun damage or healed blemishes. The cells themselves are, in essence, primed to overreact, and they remain primed for a very long time, often indefinitely, which is the central reason melasma behaves so differently from other forms of hyperpigmentation when it comes to treatment and recurrence.

There is also a structural component that recent dermatologic research has clarified considerably. Melasma is not purely a melanocyte problem sitting passively in otherwise normal skin. The affected skin shows increased blood vessel density, alterations in the basement membrane that normally helps keep pigment-containing cells properly organized, and a general disruption of the skin's architecture in ways that go well beyond "too much pigment in one place." This is part of why melasma is now understood by many dermatologic researchers as fundamentally a disorder of photoaging and vascular change with pigment as one visible consequence, rather than purely a pigmentation disorder on its own. I find this framework clinically useful because it explains a pattern I see constantly: patients whose melasma improves with pigment-targeted treatment alone, only to relapse, often because the underlying vascular and structural changes were never addressed.

The Three Triggers That Have to Line Up

Melasma does not develop from a single cause. In my clinical experience, and in the broader dermatologic literature, three factors generally have to intersect for melasma to appear and persist: genetic predisposition, hormonal influence, and light exposure, specifically including a type of light exposure that gets almost no attention in consumer skincare conversations. Understanding each of these, and how they interact, is essential to understanding why melasma is so notoriously difficult to manage with any single intervention.

Genetic predisposition is the foundation. Melasma occurs significantly more frequently in people with medium to deep skin tones, generally corresponding to Fitzpatrick skin types three through six, and a strong family history is extremely common. If your mother or a sibling has dealt with melasma, your own melanocytes likely carry a similar baseline tendency toward hyperresponsiveness. This genetic component cannot be changed, but understanding that it exists helps set realistic expectations: melasma in a genetically predisposed person is something to be controlled and managed long-term, not something to be "cured" once and never thought about again.

Hormonal influence is the second major trigger, and it is the reason melasma carries the nickname "the mask of pregnancy," technically called chloasma in that specific context, though I want to be clear that pregnancy is far from the only hormonal trigger relevant here. Estrogen and progesterone both appear to stimulate melanocyte activity directly, which is why melasma frequently first appears or significantly worsens during pregnancy, with the use of hormonal birth control, particularly estrogen-containing formulations, and in some patients, around perimenopause and with hormone replacement therapy, the same hormonal transition I have discussed in other contexts as having such a wide-ranging impact on skin. This hormonal sensitivity is part of why melasma is dramatically more common in women than in men, and why a patient's hormonal history, including pregnancies, birth control use, and any hormone therapy, is one of the first things I ask about during a melasma consultation. It directly shapes both the diagnosis and the treatment plan, including, in some cases, a conversation about whether a hormonal contraceptive switch is worth discussing with the prescribing physician.

The third trigger is light exposure, and this is where I think the most clinically important and most commonly missed information lives.

The Visible Light Problem Almost Nobody Tells You About

If you have melasma and have been told, reasonably, that sun protection is essential, you have likely been given that advice in the context of ultraviolet radiation specifically. UVA and UVB protection absolutely matters and is non-negotiable, but a substantial and growing body of dermatologic research has demonstrated that melasma-prone melanocytes are also significantly stimulated by visible light, the portion of the light spectrum that we actually see, including the blue light spectrum emitted by the sun itself, and to a real but more modest degree, by screens.

This matters enormously in practice because most sunscreens, including many labeled "broad spectrum," are formulated specifically to filter ultraviolet radiation and offer comparatively little protection against visible light. A patient can be diligently applying a broad-spectrum SPF fifty every single day, doing everything seemingly right, and still experience melasma flares driven substantially by visible light exposure that her sunscreen was never designed to block.

The clinical solution to this gap is tinted sunscreen, specifically formulations containing iron oxides, which are the ingredients capable of providing meaningful visible light protection in addition to standard UVA and UVB filtering. This is one of the most consistently underestimated recommendations in melasma management, and in my own practice, it is one of the first changes I make to a patient's routine: not simply "wear sunscreen," which most melasma patients are already doing, but "wear an iron oxide-containing tinted sunscreen, reapplied throughout the day," which addresses a trigger that an untinted formula, however high the SPF number, is largely missing. I want to be direct about this because I think it is genuinely one of the highest-value, lowest-cost adjustments available to almost any melasma patient, and it is rarely emphasized with the weight it deserves.

Why Melasma Keeps Coming Back, Even After It Clears

This is, in my experience, the single most frustrating part of melasma for patients, and I want to address it honestly rather than glossing over it the way some marketing around "melasma solutions" tends to do.

Because the underlying melanocyte hyperresponsiveness is not eliminated by treatment, only suppressed, melasma has a strong tendency to relapse once active treatment stops or once a trigger reappears. A patient who achieves excellent clearance with a well-executed treatment plan, and then becomes pregnant again, switches to a different hormonal contraceptive, has an unusually high-UV summer, or simply stops her maintenance routine, can see the same patches return, sometimes within weeks. This is not a sign that the original treatment failed or that something was done incorrectly. It is the expected natural history of a condition rooted in a durable cellular tendency rather than a one-time injury.

I think this single piece of information changes how patients relate to their own treatment more than almost anything else I can tell them. Melasma management is not a project with a finish line. It is an ongoing, generally lifelong, low-maintenance practice, similar in structure to how I think about long-term skin barrier care or sun protection generally: most of the time, a fairly modest maintenance routine keeps things controlled, and the goal is never to need the more intensive corrective phase again, rather than to declare victory and stop everything.

How Treatment Can Make Melasma Temporarily Worse, and Why That Happens

I want to address a pattern that causes a tremendous amount of patient frustration and, frankly, a tremendous amount of mistrust in dermatologic treatment generally: the experience of melasma appearing to worsen after starting a new treatment, sometimes dramatically.

Any treatment that creates meaningful inflammation in the skin, including aggressive chemical peels, certain laser and energy-based treatments, and overly enthusiastic at-home exfoliation, runs the risk of triggering a rebound response in melasma-prone melanocytes specifically because those cells are, as I described earlier, chronically primed to overreact to stimulation. Inflammation that would cause a brief, mild redness in unaffected skin can trigger a disproportionate pigment response in melasma-affected skin, producing a flare that looks, to a frustrated patient, like the treatment made things worse rather than better.

This is precisely why I am considerably more conservative with melasma than I am with most other pigmentary concerns when it comes to procedure selection and intensity. Aggressive ablative lasers, high-fluence intense pulsed light treatments, and overly deep chemical peels carry a genuinely elevated risk of triggering post-inflammatory hyperpigmentation on top of existing melasma in medium to deep skin tones, sometimes leaving a patient with more total discoloration than she started with. I have treated patients who arrived at my practice after exactly this experience elsewhere, and rebuilding both their skin and their confidence in treatment takes considerably longer than if the right, more conservative approach had been chosen from the start.

This does not mean procedures have no role in melasma treatment. It means the selection of which procedure, at what intensity, and in what sequence relative to topical preparation, requires real clinical judgment specific to melasma, not a generic "pigment treatment" protocol borrowed from sunspot or post-inflammatory hyperpigmentation management.

The Treatment Hierarchy I Actually Use

I find it useful, both for myself and for patients, to think about melasma treatment in the same tiered structure I use for most skin concerns: a foundational tier that is genuinely non-negotiable, a supportive tier built around well-evidenced topical actives, and a corrective tier where more intensive interventions, including oral medication and in-office procedures, come into play for patients who need more than topicals alone can offer.

Foundational

Sun and visible light protection, as described above, sits at the absolute foundation, and I mean this in the most literal sense: no other intervention in this entire treatment hierarchy will hold its results if this piece is not in place. A tinted, iron oxide-containing, broad-spectrum sunscreen, reapplied at least every two hours during meaningful daylight exposure, and supplemented with a wide-brimmed hat during peak sun hours, is not optional in melasma management. It is the floor beneath everything else.

Gentle, non-irritating skincare is the second foundational piece, directly connected to the inflammation-triggers-flares mechanism described above. This means avoiding harsh physical scrubs, overly aggressive acid concentrations, and any product that produces noticeable stinging, redness, or irritation. A compromised or inflamed barrier in a melasma-prone patient is not a minor cosmetic inconvenience; it is an active trigger for further pigment production.

Supportive

Within the supportive tier, several well-evidenced topical ingredients have a meaningful, well-documented role.

Topical tranexamic acid has become one of the more significant additions to melasma management in recent years. Tranexamic acid works through a mechanism distinct from most traditional pigment-lightening ingredients: rather than primarily inhibiting the pigment-producing enzyme tyrosinase, it interferes with a signaling pathway involving plasmin that influences melanocyte activity and the prostaglandin-driven inflammation that contributes to melasma's vascular component. This dual action, addressing both pigment production and the underlying vascular and inflammatory contributors, is part of why topical tranexamic acid has gained such consistent traction in recent dermatologic literature as a well-tolerated, evidence-supported option, often used in combination with other actives rather than as a standalone treatment.

Azelaic acid offers a notably gentle mechanism, inhibiting tyrosinase activity with a side benefit profile that tends to be considerably better tolerated than some alternatives, making it a frequent component of long-term maintenance routines for patients whose skin reacts poorly to more aggressive options.

Niacinamide supports this entire tier indirectly but meaningfully, interfering with the transfer of pigment granules from melanocytes to surrounding skin cells, while simultaneously supporting the barrier function that, as described above, is so directly tied to keeping melasma-prone melanocytes calm rather than triggered.

Vitamin C, alongside other topical antioxidants, supports pigment management through its own tyrosinase-inhibiting activity and its broader role in mitigating the oxidative stress that ultraviolet and visible light exposure generate in skin, complementing rather than replacing the sun protection described above.

Retinoids have a genuine, evidence-supported role in melasma through their effect on epidermal turnover and their long-term influence on pigment distribution, but they require particularly careful, gradual introduction in melasma-prone skin specifically because of the irritation-triggers-flare mechanism. This is an area where I see patients make the most missteps when self-treating: introducing a retinoid too quickly, in too high a concentration, produces exactly the kind of low-grade inflammation that can worsen the very condition the retinoid was meant to help.

Cysteamine, a newer addition to the topical melasma toolkit, has accumulated a meaningful evidence base for tyrosinase-inhibiting activity with a side benefit of working through a pathway distinct from hydroquinone, making it a useful option for patients seeking an effective alternative to hydroquinone-based regimens or needing a "treatment holiday" ingredient to rotate in periodically.

I want to address hydroquinone directly, because it remains, despite considerable consumer skepticism, one of the most extensively studied and effective topical agents for melasma when used correctly. Hydroquinone works by directly inhibiting tyrosinase, and decades of dermatologic literature support its efficacy. The legitimate concerns around hydroquinone relate almost entirely to unsupervised, prolonged, high-concentration use without appropriate breaks, which carries a real, if uncommon, risk of a condition called exogenous ochronosis, a paradoxical darkening of the skin from years of improper use. Used under appropriate physician supervision, in appropriate concentrations, for defined treatment periods with planned breaks, hydroquinone remains a legitimate and often highly effective tool. This is precisely the kind of ingredient where professional guidance changes both the safety profile and the outcome considerably compared to unsupervised self-treatment.

Corrective

For melasma that does not respond adequately to topical management alone, several corrective-tier interventions have a meaningful, evidence-supported role, though I want to emphasize again that procedure selection in melasma requires more caution and more melasma-specific expertise than in most other pigmentary conditions.

Oral tranexamic acid has emerged as one of the more significant developments in melasma treatment over the past several years, with a growing body of clinical research, including recent systematic reviews and meta-analyses, supporting meaningful efficacy, particularly for melasma resistant to topical treatment alone. Oral tranexamic acid works on the same antifibrinolytic, anti-inflammatory mechanism as the topical version, but with systemic reach that many patients find produces more consistent results than topical treatment alone can achieve. This is, importantly, a prescription medication requiring a real medical evaluation before use: tranexamic acid affects blood clotting pathways, and patients with a personal or strong family history of blood clots, certain clotting disorders, or specific other medical conditions are not appropriate candidates. This is a conversation that belongs entirely with a physician who can review a complete medical history, not a supplement to add to a routine independently, and I want to be unambiguous about that given how much enthusiasm I have seen for this treatment in places that are not appropriately screening candidates.

Microneedling combined with topical tranexamic acid has gained considerable research support as a combination approach, with the microneedling process creating temporary microchannels that meaningfully enhance the delivery and effectiveness of topical tranexamic acid applied during or immediately after the procedure. Recent clinical trial data on this specific combination has been genuinely encouraging for resistant melasma, and it is an approach I use selectively in my own practice for appropriately selected patients.

Chemical peels have a role, but a more carefully calibrated one than in most other pigmentary conditions, given the rebound risk described earlier. Lighter, more superficial peels, used judiciously and built up gradually, tend to be the more appropriate choice for melasma compared to deeper, more aggressive peel protocols, which carry meaningfully elevated risk of triggering the inflammatory rebound response this entire condition is so prone to.

Laser and energy-based treatment for melasma has evolved considerably, and the current evidence and clinical consensus favor a meaningfully more conservative approach than was common even a decade ago. Low-fluence Q-switched lasers and carefully selected fractional treatments, used at conservative settings with appropriate spacing between sessions, have a reasonable evidence base for carefully selected patients. Higher-intensity ablative lasers and aggressive intense pulsed light treatments, by contrast, carry a meaningfully elevated risk of the rebound hyperpigmentation I described earlier, particularly in medium to deep skin tones, and I approach these modalities with real caution in melasma specifically, even when I would consider them reasonable options for other pigmentary or textural concerns in the same patient.

What I Want You to Take Away About Realistic Expectations

I think the most clinically responsible thing I can tell a melasma patient, and the thing that I think the broader skincare marketing landscape does the worst job of communicating, is that the realistic goal is control, not permanent elimination. A well-executed, properly sequenced treatment plan, built around genuine sun and visible light protection, well-chosen topical actives, and corrective interventions when appropriate, can produce dramatic, genuinely life-changing improvement for the great majority of patients. What it generally cannot do is permanently change the underlying tendency of melasma-prone melanocytes to react to triggers, which means maintenance, indefinitely, is part of the deal.

I find that patients who understand this upfront have a dramatically better long-term relationship with their treatment than patients who were led to expect a one-time fix. The former group builds sustainable habits and feels successful when their skin stays controlled for years. The latter group feels like every flare is evidence of failure, which is both inaccurate and, frankly, unfair to patients who are doing everything reasonably well.

Who Should Be Thinking About This Proactively

If you have a family history of melasma, a medium to deep skin tone, are pregnant, are using or considering hormonal birth control, or are entering the perimenopausal hormonal transition I have discussed elsewhere, you fall into a genuinely higher-risk category for developing melasma, even if you have never had a flare. For this group, I think proactive visible light and UV protection, well in advance of ever seeing a patch of discoloration, is a legitimately worthwhile investment, precisely because prevention is, as is true throughout dermatology, considerably easier than correction once melanocytes have been triggered into a hyperresponsive pattern.

If you already have melasma and have tried multiple over-the-counter products without sustained success, that pattern alone is meaningful clinical information: it generally signals that single-ingredient, topical-only approaches are not sufficient for your specific case, and a more comprehensive, possibly prescription-supported and procedure-supported plan is worth discussing with a physician who treats melasma regularly, rather than continuing to rotate through new serums indefinitely.

Here in Alpharetta, Johns Creek, and across the greater Atlanta metro, our climate adds a genuinely relevant local dimension to this entire conversation. Georgia's combination of high annual UV index, long warm seasons, and significant outdoor lifestyle exposure means melasma triggers are present here for a meaningfully larger portion of the year than in many other parts of the country. I think this regional reality is worth naming directly rather than treating sun protection advice as a generic, one-size-fits-all recommendation disconnected from where patients actually live.

A Final Word on Patience

Melasma treatment operates on a timeline of months, not days or weeks, for almost every patient, regardless of how well the plan is constructed. Melanocyte behavior changes gradually, and meaningful visible improvement from a well-executed topical regimen typically takes a minimum of eight to twelve weeks to become apparent, with continued improvement over several months beyond that for many patients. I say this not to discourage anyone but because I think realistic timeline expectations are part of what separates a sustainable, successful melasma treatment relationship from a frustrating cycle of abandoning treatments too early because they "aren't working" when, in fact, they simply have not yet had time to work.

The patches on your face are not a reflection of anything you did wrong, and they are not a permanent verdict on your skin. They are the visible expression of a specific, well-understood biological tendency that responds meaningfully to the right combination of protection, the right topical actives, the right professional support when needed, and, most of all, patience and consistency over time. That combination, applied correctly and maintained, is what actually controls melasma, far more reliably than any single product or procedure ever could on its own.

May your skin always glow as brightly as your smile!

~ Dr. Lazuk

CEO & Co-Founder

Dr. Lazuk Cosmetics® | Lazuk Esthetics®

Alpharetta, GA | Johns Creek, GA | Milton, GA | Suwanee, GA

Professional Credentials: https://www.skindoctor.ai/professional-creditials-disclosure-iryna-lazuk-md

If you're curious to experience this approach for yourself, our AI Facial Skincare Analysis is designed to be educational, conservative, and pressure-free, whether you're just beginning to address pigmentation concerns or preparing for an in-person consultation.

Confidential: Photos are never stored on our system, and your information is governed by HIPAA Compliance.

Explore the AI Skin Analysis

Quick Checklist: Before You Start Your Facial Skin Analysis

• Wash your face gently and leave your skin bare

• Do not wear makeup, sunscreen, or tinted products

• Avoid heavy creams or oils before analysis

• Use natural lighting when possible

• Relax your face (no smiling or tension)

• Take the photo straight on, at eye level

• Repeat the analysis every 30 days to track progress

FAQs - Melasma

What is the difference between melasma and a regular sunspot?

A sunspot, or solar lentigo, is a localized cluster of melanocytes damaged by cumulative ultraviolet exposure, producing a well-defined, isolated dark spot. Melasma involves chronically hyperresponsive melanocytes spread across broader, typically symmetrical areas of the face, with additional vascular and structural changes in the affected skin. The mechanisms, the appearance, and the appropriate treatment approach are meaningfully different between the two, which is why an accurate diagnosis matters before starting treatment.

Why does my melasma keep coming back even after my skin clears up?

Treatment generally suppresses melasma's pigment production rather than permanently changing the underlying hyperresponsive tendency of the affected melanocytes. When a trigger reappears, whether renewed sun or visible light exposure, a hormonal shift, or simply discontinuing a maintenance routine, the same cells can reactivate. This is the expected natural history of melasma, not a sign that prior treatment failed.

Why do dermatologists recommend tinted sunscreen specifically for melasma?

Most sunscreens are formulated primarily to filter ultraviolet radiation and provide limited protection against visible light, which research has shown can independently stimulate melasma-prone melanocytes. Tinted sunscreens containing iron oxides provide meaningful visible light protection in addition to standard UVA and UVB filtering, addressing a trigger that an untinted sunscreen, regardless of its SPF number, typically does not adequately cover.

Can hormonal birth control cause or worsen melasma?

Yes. Estrogen and progesterone both appear to stimulate melanocyte activity, and many patients notice melasma onset or worsening after starting hormonal birth control, particularly estrogen-containing formulations. This is worth discussing with your prescribing physician if you have a strong melasma history or family history, as alternative contraceptive options may be appropriate to consider alongside dermatologic treatment.

Is oral tranexamic acid safe for melasma treatment?

Oral tranexamic acid has meaningful clinical evidence supporting its effectiveness for melasma resistant to topical treatment, but it is a prescription medication that affects blood clotting pathways. It requires a thorough medical evaluation before use and is not appropriate for patients with a personal or strong family history of blood clotting disorders. This decision should always be made in consultation with a physician who can review your complete medical history.

Why did my melasma get worse after a chemical peel or laser treatment?

Melasma-prone melanocytes are chronically primed to overreact to inflammation. Treatments that create significant inflammation in the skin, including aggressive peels and certain high-intensity laser or light-based treatments, can trigger a disproportionate pigment rebound in melasma-affected skin, sometimes producing more visible discoloration than was present before treatment. This is why conservative, melasma-specific procedure selection matters considerably more here than in most other pigmentary concerns.

What is the role of azelaic acid in melasma treatment?

Azelaic acid inhibits tyrosinase, the enzyme responsible for pigment production, and is generally well tolerated even in sensitive or reactive skin. It is frequently used as part of a long-term maintenance routine for melasma, particularly for patients whose skin does not tolerate more aggressive topical options well.

Is hydroquinone still considered safe and effective for melasma?

Hydroquinone remains one of the most extensively studied and effective topical treatments for melasma when used under appropriate physician supervision, at appropriate concentrations, for defined treatment periods with planned breaks. The legitimate safety concerns relate to unsupervised, prolonged, high-concentration use without breaks, which carries a rare but real risk of a condition called exogenous ochronosis. Supervised, properly structured use has a strong evidence base.

How long does it take to see improvement in melasma treatment?

Most well-executed topical regimens require a minimum of eight to twelve weeks before meaningful visible improvement becomes apparent, with continued improvement over additional months for many patients. Melasma does not respond on the timeline of a typical skincare product, and realistic expectations around this timeline meaningfully improve treatment adherence and satisfaction.

Can microneedling help treat melasma?

Microneedling combined with topical tranexamic acid applied during or immediately after the procedure has growing clinical research support, with the microneedling process enhancing the delivery and effectiveness of the topical active. This combination approach is used selectively for appropriately selected, resistant melasma cases rather than as a universal first-line treatment.

Why is melasma more common in women than men?

Melasma's strong connection to hormonal triggers, particularly estrogen and progesterone fluctuations from pregnancy, hormonal birth control, and perimenopause, is the primary reason it occurs significantly more frequently in women. Genetic predisposition and skin tone also play meaningful roles independent of hormonal factors.

Does melasma only affect certain skin tones?

Melasma occurs significantly more frequently in people with medium to deep skin tones, generally corresponding to Fitzpatrick skin types three through six, though it can occur in lighter skin tones as well. A strong family history is common across all affected skin tones.

What ingredients should I avoid if I have melasma?

Harsh physical scrubs, high-concentration acids used too frequently, and any product that produces noticeable stinging or visible irritation should generally be avoided, since the resulting inflammation can trigger a disproportionate pigment response in melasma-prone skin. Introducing any new active ingredient gradually, including retinoids, is considerably safer than introducing it at full strength immediately.

Can melasma go away permanently on its own?

For most patients with a genetic predisposition, melasma does not resolve permanently on its own, even with strict avoidance of known triggers, because the underlying melanocyte hyperresponsiveness tends to persist. Some patients do see significant fading after a triggering event resolves, such as after pregnancy or after discontinuing a hormonal medication, but ongoing sun and visible light protection generally remains necessary to prevent recurrence.

What is the difference between melasma treatment and treatment for everyday dark spots or post-acne marks?

Everyday dark spots and post-acne marks generally respond well to standard tyrosinase-inhibiting ingredients and gentle exfoliation without the same rebound risk that melasma carries. Melasma requires a more comprehensive approach that addresses visible light protection specifically, accounts for hormonal triggers, and uses more conservative procedure selection to avoid triggering the inflammatory rebound response that is unique to melasma's underlying biology.

How to get started with your treatments with Lazuk Esthetics?

At Lazuk Esthetics in Alpharetta, we like to keep things super simple and work out what means of communication works best for you. Whether it's by phone, email, personal concierge, or you want us to send a car, we are here to serve you. You can get started now by visiting https://www.skindoctor.ai/lazuk-esthetics-alpharetta-ga.

Entertainment-only medical disclaimer: This content is for educational and entertainment purposes only and is not intended as medical advice. Individual skin needs vary and should be evaluated by a licensed professional.